Compare Abbott Laboratories (ABT) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Abbott Laboratories trades at $112.44 (market cap $191.92B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $15.46M). The key difference: Abbott Laboratories is far larger — about 12414× Avalanche Treasury Corporation Class A Common Stock's market cap, and Abbott Laboratories pays a 2.27% dividend while Avalanche Treasury Corporation Class A Common Stock pays none. Which is the better fit depends on your goals.
| ABT | AVAT | |
|---|---|---|
Market Cap | $191.92B | $15.46M |
Sector | Health | Financials |
52-Week High | $136.62 | $10.75 |
52-Week Low | $82.57 | $0.30 |
Enterprise Value | $218.92B | $15.46M |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.02% with strong analyst support (75.6% buy ratings) and a $120.70 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026. Fundamentals remain solid with $44.33B revenue, 11.65% net margin, and improving cash flow trends. Recent CE Mark approval for Libre Duo glucose-ketone sensors highlights innovation momentum.
ABT presents a compelling investment case with strong fundamentals, positive analyst sentiment, and innovative product pipeline. Key risks include competitive pressures in medical devices and potential macroeconomic headwinds affecting healthcare spending. The stock's current valuation at 35.15 P/E appears reasonable given growth prospects and dividend stability.
AVAT trades at $0.3426, up 1.75% today, with a bearish technical signal from moving averages and a P/E of 12. The company reported net income of $8.28 million for 2025, but negative operating cash flow of $930,710 raises concerns about liquidity. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is mixed: profitability and low valuation offer potential upside, but cash flow challenges and bearish technicals present risks. Investor sentiment is cautious due to operational losses, though the public listing may attract institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
